GLP-1/glucagon co-agonists The development of these unimolecular formulations targeting both GLP-1 and glucagon receptors enhances the anorectic effect of GLP-1, provides a lipolytic and lipogenesis-inhibiting effect (Table 2)particularly at the hepatic leveland promotes thermogenic activity, thereby facilitating weight reduction and the treatment of MASLD.1,5,35 Survodutide generates dose-dependent weight reduction of up to 14.9% in 46 weeks.49 It is shown to be effective in reducing liver fat and improving MASH in up to 62% of participants treated with weekly injection of 4.8 mg
By helping to fill the space within your tissues and between your cells, HA supports the growth of cartilage and bone, and helps maintain the integrity of your cells
For melanin assays, each condition was performed in duplicate: one well was used for melanin extraction, and the other for cell counting
If the goal is maximizing glutathione synthesis and the person tolerates NAC well, that route may be worth considering with the understanding that GI side effects could overlap with GLP-1 effects
FDA-Noted Concerns: Increased heart rate Systemic vasodilatory reactions Limited clinical safety data Immunogenicity risk (antibody formation) Reported Side Effects: Injection site reactions (redness, swelling, itching) Headache Flushing Dizziness Nausea Water retention Serious Concerns: Potential for glucose metabolism disruption Theoretical cancer risk (GH/IGF-1 promote cell proliferation) Long-term safety unknown Regulatory Status United States: CJC-1295 is not FDA approved for any indication
& Prez-Fras, J
